20250902-开源证券-华海药业-600521.SH-公司信息更新报告_2025上半年业绩有所波动_在研项目快速推进_4页_881kb

Huahai Pharmaceutical (600521.SH): Analysts maintain a "buy" rating, citing progress in in研项目 and financial performance despite a slight revenue decline in the first half of 2025. Key points include revised earnings projections for 2025-2027, with R&D expenses increasing due to advancing clinical trials. Risk factors involve potential delays in new drug approvals and market uncertainties.